About
Engineered regulatory T cells
Areas of Focus
Categories
Stem Cell & Cellular TherapyBoston & New England
Team (55)
Aaron Deykin, MD
CMO, Head of R&D, Upstream Bio, Board Director
GentiBio
board_memberexecutive
Abby Doherty, BS
Senior Research Associate
GentiBio
team_member
Adam Cotton, PhD, MBA
Associate, Novartis Venture Fund (NVF), Board Observer
GentiBio
team_member
Adan Jaramillo, BA
Senior Director, Quality
GentiBio
team_member
Alexa Perdikis, BS
Director, Human Resources
GentiBio
team_member
Amy Jennings, PhD
Principal, RegPath Consulting
GentiBio
team_member
Clinical Trials (2)
View allTotal Trials
2
As Lead Sponsor
2
As Collaborator
0
Total Enrollment
66
By Phase
PHASE1: 1
By Status
RECRUITING: 2
Clinical Trials Pipeline2 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2024
2025
2026
2027
2028
2029
Today
Hover over trial bars to see details
Recent Trials
NCT06919354Lead Sponsor
A Study of GNTI-122 in Adults Recently Diagnosed With T1D
PHASE1Recruiting
16 participants
Started: Sep 3, 2025 · Completed: Feb 29, 2028
NCT06860516Lead Sponsor
HLA Demographics Study in Adults With Type 1 Diabetes
N/ARecruiting
50 participants
Started: Jun 6, 2025 · Completed: Jun 30, 2026
Locations (1)
Headquarters
Cambridge, MA, United States
Map
Loading map...